%0 Journal Article
%T 非小细胞肺癌组织中RBM3的表达及其与患者预后的相关性研究
Expression of RBM3 in Non-Small Cell Lung Cancer and Its Correlation with Prognosis of Patients
%A 黄东帅
%A 田金
%A 郭成业
%J Advances in Clinical Medicine
%P 3088-3103
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.133440
%X 目的：探讨RBM3 (RNA结合基序蛋白3，RNA binding motif protein 3)在非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC)组织中的表达情况及其与患者临床病理学参数和预后的关系。方法：收集2014年8月1日至2015年8月1日在青岛市市立医院东院区胸外科行肺癌根治术的135例NSCLC患者，通过免疫组化染色方法检测RBM3的表达情况，通过卡方检验分析其与患者临床病理学参数的相关性，采用Kaplan-Meier法、log-rank检验法和Cox比例风险模型统计RBM3表达与患者OS (总生存期)及PFS (无进展生存期)的关系。结果：RBM3的表达与肿瘤组织分化程度(P = 0.015)、N分期(P = 0.005)、T分期(P = 0.032)、LVD (淋巴管密度，以D2-40进行标记) (P = 0.039)及MVD (微血管密度，以CD34进行标记) (P = 0.035)明显相关，差异具有统计学意义(P < 0.05)；单因素Cox回归分析表明：RBM3的表达、肿瘤组织分化程度、LVD、MVD、T分期、N分期是影响非小细胞肺癌的OS的因素(P < 0.05)；RBM3的表达、肿瘤组织分化程度、LVD、MVD、N分期是影响非小细胞肺癌的PFS的因素(P < 0.05)；Cox比例风险模型多因素分析表明，RBM3、N分期、T分期及LVD、MVD是影响NSCLC患者OS及PFS的独立危险因素(P < 0.05)。生存分析提示低表达RBM3患者的OS、PFS明显长于高表达RBM3的患者。结论：RBM3、N分期、T分期、LVD、MVD是非小细胞肺癌独立的预后因素。RBM3可能成为非小细胞肺癌总体生存率的预后标志物，并可能成为非小细胞肺癌治疗的潜在靶点，具有广阔的治疗前景。
Objective: To investigate the expression of RBM3 (RNA binding motif protein 3) in non-small cell lung cancer (NSCLC) tissues and its relationship with clinical pathological parameters and prognosis of patients. Methods: A total of 135 patients with NSCLC who underwent radical resection of lung cancer in Department of Chest Surgery, Qingdao Municipal Hospital East Campus from August 1, 2014 to August 1, 2015 were collected. The expression of RBM3 was detected by immunohisto-chemistry, and its correlation with clinical pathological parameters was analyzed by Chi square test. The Kaplan-Meier method, log-rank test and Cox proportional risk model were used to calculate the relationship between RBM3 expression and OS (overall survival) and PFS (progression-free survival) of the patients. Results: The expression of RBM3 was significantly correlated with the degree of dif-ferentiation (P = 0.015), N-stage (P = 0.005), T-stage (P = 0.032), LVD (lymphatic vessel density, la-beled with D2-40) (P = 0.039) and MVD (microvessel density, labeled with CD34) (P = 0.035) (both P < 0.05). Univariate Cox regression analysis showed that the expression of RBM3, tumor tissue dif-ferentiation, LVD, MVD, T-stage, and N-stage were the factors affecting OS in NSCLC (P < 0.05). The expression of RBM3, the differentiation degree of tumor tissue, LVD, MVD, and N-stage were the fac-tors that affected the PFS of NSCLC (P < 0.05). Multivariate analysis using Cox proportional hazards model showed that RBM3, N-stage, T-stage, LVD and MVD were the independent risk factors for OS and PFS in patients with NSCLC (P < 0.05). Survival analysis indicated that the OS and PFS of pa-tients with low expression of RBM3 were significantly longer than those of patients with high ex-pression of RBM3.
%K 非小细胞肺癌，RBM3，临床病理学特征，OS，PFS
Non-Small Cell Lung Cancer
%K RBM3
%K Clinicopathological Features
%K OS
%K PFS
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=62251